Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05163587
Other study ID # Composite flour
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 26, 2021
Est. completion date December 30, 2021

Study information

Verified date January 2024
Source University of Veterinary and Animal Sciences, Lahore - Pakistan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A low glycemic multigrain flour for chapattis will be made from grains and cereals that are easily available in Pakistan. The nutritional profile and composition of test flour will be checked through proximate analysis method determined by AOAC. GI of test flour will be determined by comparing it with a reference food. The participants will be fed reference food i.e., 50gm glucose dissolved in 250ml water and test food serving having 50gm of available carbohydrates separately after an overnight fast. Finger prick method will be used to determine blood glucose levels at 0,15, 30, 45, 90 minutes. Trapezoidal rule will be used to determine iAUC and GI and GL will be determined by using standard formulas. Efficacy of test flour will be checked by human clinical trial. Control group will be fed chapatis made from test flour for 90 days. Anthropometry, body composition and biochemical measures including HbA1c, blood glucose (fasting and random) and lipid profile will be analyzed pre- and post-intervention and differences in their readings will be compared.


Description:

The study comprises of four different phases. - Phase 1: To develop a low GI composite flour. - Phase 2: To assess nutritional profile and composition of the composite flour. - Phase 3: To determine GI of chapatis made from test flour. - Phase 4: Test the efficacy of test flour in improving glycemic profile through clinical trial. Subjects: A total of 30 Type 2 diabetic patients aged between 30-60 years that are on oral medication will be selected for participation. They can be of either sex with no other complications of the disease. A written consent from the participants will be taken prior to study. Those participants who have insulin dependency, thyroid issues, are smokers and pregnant and lactating mothers will be excluded from the study. Prior to study, anthropometric measurements that will include height, weight, BMI, hip to waist ratio of each participant will be done. All the participants will complete testing for their HbA1c, lipid profile, fasting and random blood glucose measurements prior to study. For this, they will be called to University of Veterinary and Animal Sciences, Lahore for their blood sample collection. All the participants will be divided into two groups: control and intervention group with 15 participants in each group. The study will be conducted for 90 days and only those participants will be recruited that will be willing to complete the study duration with all the protocols for it. These include no major change in dietary pattern during the study. No change in physical activity i.e. doing any intense exercise or following any new workout routines. No change in medications or supplements during the study period is recommended. Experimental design: The participants in the intervention group will be provided test flour for their chapattis (2kg for 10 days). The flour will be provided after each 10 days and they will be asked to use this flour for their chapattis. They will be guided to consume at least 3-4 chapattis each day while the participants in the control group will be asked to continue the flour, they are already using for their chapatti making. However during the study period all the participants will continue to follow their regular dietary habits, physical activity patterns and will continue taking their diabetes medication as per their schedule. Biochemical testing: Along with the anthropometry, the participants will be tested biochemically by taking their blood samples at the start and at the end of the study. Before starting the trial, each participant will be tested for HbA1c and lipid profile. HbA1c tests will be done by Ion Exchange Resin method by using Glycohemoglobin HbA1 kit of brand Human Diagnostics. Lipid profile will also be checked at the baseline and after 3 months. For this purpose, Human diagnostic Kit will be used i.e. cholesterol liquicolor kit for cholesterol assessment, HDL cholesterol kit by Human diagnostics for HDL measurement, LDL liquicolor kit and TG Liquicolor mono kit by Human Diagnostics for LDL and triglycerides assessment. Random and Fasting blood glucose levels will be checked after every 10 days by using finger prick method through Glucometer (ACCU-CHECKĀ® Performa Nano, Mannhim, Germany). For their interpretation, Guidelines of National Cholesterol Education Program (NCEP), (2004) will be used. Statistical analysis: Statistical Package for Social Science software ( version 22) will be used for data analysis. Independent t test will be applied to check the differences between control and intervention groups. Paired t test will be used to determine differences among groups at initial and final time points within a group and their association will be checked at significance level of <0.05. Repeated measure design will be used to compare the blood glucose levels after every 10 days.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date December 30, 2021
Est. primary completion date December 5, 2021
Accepts healthy volunteers No
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: - type 2 diabetic patients of either sex that are non insulin dependent between age 30-60 years that are on oral medication only Exclusion Criteria: - patients with biochemical evidence of other diseases, thyroid patients, pregnant and lactating mothers and those above the age of 60 years or those who use insulin to control their blood glucose levels

Study Design


Intervention

Combination Product:
low GI composite flour
low GI composite flour orally in chapati form (3times/day)

Locations

Country Name City State
Pakistan University of Veterinary and Animal Sciences, Paksitan Lahore Punjab

Sponsors (1)

Lead Sponsor Collaborator
University of Veterinary and Animal Sciences, Lahore - Pakistan

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary hbA1c by using low GI composite flour, the blood glucose levels of patients with type 2 diabetes should be controlled in a better way that can be determined by their hbA1c test value in 90 days 90 days
Primary blood glucose levels by incorporating low GI food in daily meals will help lower the readings of daily blood glucose levels in patients with type 2 diabetes weekly
Primary lipid profile lipid profile of patients with type 2 diabetes will be improved 90 days
Secondary body weight by keeping blood glucose levels in control and incorporating high fiber multigrain flour, it is expected that body weight of diabetic type 2 patients will be controlled in better way. 90 days
Secondary body composition body composition of participants will be measured through BIA 90days
See also
  Status Clinical Trial Phase
Completed NCT03793985 - Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337 Phase 1
Recruiting NCT03947866 - Ezetimibe-Rosuvastatin Evaluation Study
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Completed NCT04516291 - A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) Phase 2
Completed NCT04701775 - Effect of Different Probiotic Strains in Hypercholesterolemic Patients N/A
Completed NCT03632668 - Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072 Phase 1
Completed NCT03534661 - L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release Phase 2/Phase 3
Completed NCT03422666 - Plasma Lipoprotein Response to Glucagon-like Peptide-2 Phase 2/Phase 3
Completed NCT00536796 - Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets N/A
Completed NCT03643705 - A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention N/A
Recruiting NCT04560296 - Community-based E-Health Program for Older Adults Living With Chronic Diseases N/A
Terminated NCT04073134 - The CHORAL Flow Study Phase 4
Recruiting NCT05103254 - Bempedoic Acid Pregnancy Surveillance Program
Not yet recruiting NCT05015348 - Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients With Hyperlipidemia N/A
Active, not recruiting NCT05082350 - Nutritional Intervention With Black Garlic N/A
Not yet recruiting NCT04398771 - To Evaluate Safety and Effectiveness of RovatitanTab.
Not yet recruiting NCT04064281 - The Healthy Cantonese Diet on Cardiometabolic Syndrome N/A
Recruiting NCT06257641 - Impact of the Mediterranean Diet on Patients With Psoriasis N/A
Completed NCT03690778 - The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers. Phase 1
Completed NCT04354987 - Compare the Pharmacokinetics and Safety of CKD-391 Phase 1